Table 1

Randomised controlled trials with proangiogenic factors

FamilyTherapeutic factorTrial namePhaseAdministrationPatients with ICM cohortNumber of participantsMain effect
VEGFVEGF-A165VIVA28IIIC and intravenousCCS II–III178High-dose improved CCS class. Trend in exercise time and angina frequency but not myocardial perfusion
AdVEGF165 or plasmid/liposome VEGF165KAT33 34IIICCCS II–III for PCI103Improved myocardial perfusion at 6 months
AdVEGF121REVASC31IIIM minithxCCS II–IV67Improved time to 1 mm ST-segment depression on ECG at 26 weeks but not myocardial perfusion
AdVEGF121NOVA32I/IIIM PCCCS II–IV17/129(premature termination)Negative effect. Premature termination
VEGF165 plasmidEUROINJECT-ONE29II/IIIIM PCCCS III–IV74Negative. No difference in myocardial perfusion
VEGF165 plasmidNORTHERN30II/IIIIM PCCCS III–IV120Negative. No difference in myocardial perfusion
FGFrFGF-2Laham et al36I/IIEpicardial implantation in ungraftable areaCCS III–IV for CABG24Improvement in angina symptoms and myocardial perfusion at 3 years with high dose
rFGF-2FIRST37IIICCCS III–IV337Trend towards 3 month improvement in angina. No effect on exercise time or myocardial perfusion
Ad5-FGF4AGENT38I/IIICCCS II–III79Improved exercise time
Ad5-FGF4AGENT-239IIICCCS II–IV52Improved myocardial perfusion
Ad5-FGF4AGENT-340IIIICCCS II–IV416Negative with a low dose
Ad5-FGF4AGENT-440IIIICCCS II–IV116Improved exercise time and tolerance with high dose, only in women
  • CABG, coronary artery bypass grafting; CCS, Canadian Cardiovascular Society angina class (I–IV); IC, intracoronary; ICM, ischaemic cardiomyopathy; IM, intramyocardial; minithx, mini-invasive thoracotomy; PC, percutaneous; PCI, percutaneous coronary intervention.